Search This Blog

Tuesday, April 9, 2019

Encouraging Economic Outcomes for Medtronic HeartWare HVAD System

Medtronic plc (NYSE:MDT) today announced data showing promising economic outcomes for the Medtronic HeartWare HVAD System after analyzing multiple clinical studies.
The economic analyses of the HVAD System – a left ventricular assist device (LVAD) that helps a failing heart pump and increases the amount of blood that circulates through the body – were presented at the 2019 International Society for Heart and Lung Transplantation (ISHLT) Scientific Sessions.
The first analysis showed that heart failure patients who received the HVAD System through a less-invasive thoracotomy procedure in the LATERAL study incurred lower hospitalization and medical supply costs than patients who received a ventricular assist device (VAD) through the traditional sternotomy implant procedure. The average total cost per patient in the thoracotomy (LATERAL) study was $204,107 compared to $260,492 for (non-study) traditional median sternotomy VAD cases

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.